title: Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.
abstract: Drug discrimination studies for assessment of psychoactive properties of drugs in safety pharmacology and drug abuse and drug dependence potential evaluation have traditionally been focused on testing novel compounds against standard drugs for which drug abuse has been documented, e.g. opioids, CNS stimulants, cannabinoids etc. (e.g. Swedberg & Giarola, 2015), and results are interpreted such that the extent to which the test drug causes discriminative effects similar to those of the standard training drug, the test drug would be further characterized as a potential drug of abuse. Regulatory guidance for preclinical assessment of abuse liability by the European Medicines Agency (EMA, 2006), the U.S. Food and Drug Administration (FDA, 2010), the International Conference of Harmonization (ICH, 2009), and the Japanese Ministry of Health Education and Welfare (MHLW, 1994) detail that compounds with central nervous system (CNS) activity, whether by design or not, need abuse and dependence liability assessment. Therefore, drugs with peripheral targets and a potential to enter the CNS, as parent or metabolite, are also within scope (see Swedberg, 2013, for a recent review and strategy). Compounds with novel mechanisms of action present a special challenge due to unknown abuse potential, and should be carefully assessed against defined risk criteria. Apart from compounds sharing mechanisms of action with known drugs of abuse, compounds intended for indications currently treated with drugs with potential for abuse and or dependence are also within scope, regardless of mechanism of action. Examples of such compounds are analgesics, anxiolytics, cognition enhancers, appetite control drugs, sleep control drugs and drugs for psychiatric indications. Recent results (Swedberg et al., 2014; Swedberg & Raboisson, 2014; Swedberg, 2015) on the metabotropic glutamate receptor type 5 (mGluR5) antagonists demonstrate that compounds causing hallucinatory effects in humans did not exhibit clear discriminative effects when tested against classical drugs of abuse in drug discrimination studies, and were not self-administered by rats. However, these compounds did cause salient discriminative effects of their own in animals trained to discriminate them from no drug. Therefore, from a safety pharmacology perspective, novel compounds that do not cause discriminative effects similar to classical drugs of abuse, may still cause psychoactive effects in humans and carry the potential to maintain drug abuse, suggesting that proactive investigation of drug abuse potential is warranted (Swedberg, 2013). These and other findings will be discussed, and the application of drug discrimination procedures beyond the typical standard application of testing novel compounds against known and well characterized reference drugs will be addressed.
authors.affiliation: Swedberg Preclinical Partner AB (Inc.), Sockengatan 6, S-61933 Trosa, Sweden. Electronic address: michael.swedberg@telia.com.
authors.forename: Michael D B
authors.initials: MD
authors.lastname: Swedberg
mesh_terms: D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000633:toxicity*; D002493:Central Nervous System Diseases / Q000139:chemically induced*; D004192:Discrimination, Psychological / Q000187:drug effects*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D012449:Safety; D019966:Substance-Related Disorders / Q000523:psychology*
chemical_list: D002491:Central Nervous System Agents
keywords: CNS; Central nervous system; Drug abuse liability; Drug dependence; Drug discrimination; PNS; Peripheral nervous system; Psychoactive; Regulatory; Strategy